The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.
A recent modification to the contract would have allowed Vaxart to invoice BARDA for the remaining $230 million or so for ...
Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.
Equities researchers at Zacks Research raised their Q3 2025 earnings estimates for Pfizer in a report issued on Monday, February 24th. Zacks Research analyst K. Shah now forecasts that the ...